Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Bressan, R. A. Articles by Pilowsky, L. S. Search for Related Content PubMed Citation Articles by Bressan, R. A. Articles by Pilowsky, L. S. Neurotransmitters Schizophrenia Spectrum Disorders Atypical Neuroleptics

Is Regionally Selective D₂/D₃ Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [¹²³I]Epidepride SPET Study of Amisulpride-Treated Patients

OBJECTIVE: Atypical antipsychotic drug treatment is clinically effective with a low risk of extrapyramidal symptoms. Explanations for the mechanism underlying this beneficial therapeutic profile of atypical over typical antipsychotic agents include 1) simultaneous antagonism of dopamine D₂ and serotonin 5-HT_2A receptors or 2) selective action at limbic cortical dopamine D₂-like receptors with modest striatal D₂ receptor occupancy. Amisulpride is an atypical antipsychotic drug with selective affinity for D₂/D₃ dopamine receptors and provides a useful pharmacological model for examining these hypotheses. The authors’ goal was to evaluate whether treatment with amisulpride results in "limbic selective" D₂/D₃ receptor blockade in vivo. METHOD: Five hours of dynamic single photon emission tomography data were acquired after injection of [¹²³I]epidepride (approximately 150 MBq). Kinetic modeling was performed by using the simplified reference region model to obtain binding potential values. Estimates of receptor occupancy were made relative to a healthy volunteer comparison group (N=6). RESULTS: Eight amisulpride-treated patients (mean dose=406 mg/day) showed moderate levels of D₂/D₃ receptor occupancy in the striatum (56%), and significantly higher levels were seen in the thalamus (78%) and temporal cortex (82%). CONCLUSIONS: Treatment with amisulpride results in a similar pattern of limbic cortical over striatal D₂/D₃ receptor blockade to that of other atypical antipsychotic drugs. This finding suggests that modest striatal D₂ receptor occupancy and preferential occupancy of limbic cortical dopamine D₂/D₃ receptors may be sufficient to explain the therapeutic efficacy and low extrapyramidal symptom profile of atypical antipsychotic drugs, without the need for 5-HT_2A receptor antagonism.

This article has been cited by other articles:

				J. M. Stone, J. M. Davis, S. Leucht, and L. S. Pilowsky Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature Schizophr Bull, February 26, 2008; (2008) sbn009v1. [Abstract] [Full Text] [PDF]

				A. A. Gibbs, K. H. Naudts, E. P. Spencer, and A. S. David The Role of Dopamine in Attentional and Memory Biases for Emotional Information Am J Psychiatry, October 1, 2007; 164(10): 1603 - 1609. [Abstract] [Full Text] [PDF]

				J. M. Stone, P. D. Morrison, and L. S. Pilowsky Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review J Psychopharmacol, June 1, 2007; 21(4): 440 - 452. [Abstract] [PDF]

				G. Remington, D. Mamo, A. Labelle, J. Reiss, C. Shammi, E. Mannaert, S. Mann, and S. Kapur A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone Am J Psychiatry, March 1, 2006; 163(3): 396 - 401. [Abstract] [Full Text] [PDF]

				L. K. Tremblay, C. A. Naranjo, S. J. Graham, N. Herrmann, H. S. Mayberg, S. Hevenor, and U. E. Busto Functional Neuroanatomical Substrates of Altered Reward Processing in Major Depressive Disorder Revealed by a Dopaminergic Probe Arch Gen Psychiatry, November 1, 2005; 62(11): 1228 - 1236. [Abstract] [Full Text] [PDF]

				C. la Fougere, E. Meisenzahl, G. Schmitt, J. Stauss, T. Frodl, K. Tatsch, K. Hahn, H.-J. Moller, and S. Dresel D2 Receptor Occupancy During High- and Low-Dose Therapy with the Atypical Antipsychotic Amisulpride: A 123I-Iodobenzamide SPECT Study J. Nucl. Med., June 1, 2005; 46(6): 1028 - 1033. [Abstract] [Full Text] [PDF]

				R. A. BRESSAN, K. ERLANDSSON, R. S. MULLIGAN, R. N. GUNN, V. J. CUNNINGHAM, J. OWENS, P. J. ELL, and L. S. PILOWSKY Evaluation of NMDA Receptors in Vivo in Schizophrenic Patients with [123I]CNS 1261 and SPET: Preliminary Findings Ann. N.Y. Acad. Sci., November 1, 2003; 1003(1): 364 - 367. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us